NO961639D0 - Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav - Google Patents

Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav

Info

Publication number
NO961639D0
NO961639D0 NO961639A NO961639A NO961639D0 NO 961639 D0 NO961639 D0 NO 961639D0 NO 961639 A NO961639 A NO 961639A NO 961639 A NO961639 A NO 961639A NO 961639 D0 NO961639 D0 NO 961639D0
Authority
NO
Norway
Prior art keywords
recombinant adenovirus
adenovirus vector
vector
protein
dna
Prior art date
Application number
NO961639A
Other languages
English (en)
Other versions
NO961639L (no
Inventor
Richard J Gregory
Ken N Wills
Daniel C Maneval
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO961639D0 publication Critical patent/NO961639D0/no
Publication of NO961639L publication Critical patent/NO961639L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
NO961639A 1993-10-25 1996-04-24 Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav NO961639L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14266993A 1993-10-25 1993-10-25
US24600694A 1994-05-19 1994-05-19
PCT/US1994/012235 WO1995011984A2 (en) 1993-10-25 1994-10-25 Recombinant adenoviral vector and methods of use

Publications (2)

Publication Number Publication Date
NO961639D0 true NO961639D0 (no) 1996-04-24
NO961639L NO961639L (no) 1996-06-24

Family

ID=26840311

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961639A NO961639L (no) 1993-10-25 1996-04-24 Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav

Country Status (21)

Country Link
US (5) US20080182807A1 (no)
EP (3) EP0797676B9 (no)
JP (1) JP3875990B2 (no)
CN (1) CN1263864C (no)
AT (2) ATE314482T1 (no)
AU (1) AU687117B2 (no)
BR (1) BR9407956A (no)
CA (1) CA2173975C (no)
CZ (1) CZ291372B6 (no)
DE (2) DE69435223D1 (no)
DK (1) DK0797676T3 (no)
ES (2) ES2328585T3 (no)
FI (1) FI961755A (no)
HU (1) HU223733B1 (no)
NO (1) NO961639L (no)
NZ (1) NZ275956A (no)
PL (1) PL186073B1 (no)
PT (1) PT797676E (no)
RU (1) RU2162342C2 (no)
SK (1) SK283703B6 (no)
WO (1) WO1995011984A2 (no)

Families Citing this family (334)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
RU2162342C2 (ru) * 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
AU4503796A (en) * 1994-11-28 1996-06-19 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU718772B2 (en) * 1995-03-24 2000-04-20 Genzyme Corporation Adenovirus vectors for gene therapy
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6132989A (en) * 1996-06-03 2000-10-17 University Of Washington Methods and compositions for enhanced stability of non-adenoviral DNA
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
EP1471146B1 (en) * 1996-09-25 2009-01-07 Novartis AG A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
ES2136583T1 (es) * 1996-10-18 1999-12-01 Canji Inc Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU742696B2 (en) * 1996-11-18 2002-01-10 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
ES2283032T3 (es) * 1996-12-13 2007-10-16 Schering Corporation Metodos para purificar virus.
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors
US6146891A (en) * 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6200799B1 (en) * 1997-06-03 2001-03-13 University Of Lausanne Somatic gene therapy to suppress secondary cataract formation following eye surgery
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
PL197747B1 (pl) 1998-02-17 2008-04-30 Schering Corp Kompozycja zawierająca adenowirusa, sposoby zatężania preparatu wirusa oraz sposób oczyszczania preparatu wirusa
EP2261343A3 (en) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO1999058156A1 (en) * 1998-05-12 1999-11-18 Baylor College Of Medicine Cancer prevention by selective delivery methods
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU6497799A (en) * 1998-10-15 2000-05-01 Canji, Inc. Methods and compositions to induce antitumor response
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
WO2000029573A2 (en) * 1998-11-18 2000-05-25 Canji, Inc. Adenoviral vectors
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
EP1232264B1 (en) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Human fgf-21 gene and gene expression products
BRPI0107679B8 (pt) 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
EP1284294A4 (en) 2000-05-26 2004-10-13 Sumitomo Pharma NOVEL RECOMBINANT ADENOVIRUS VECTOR WITH REDUCED SIDE EFFECTS
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2305087T3 (es) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
DE10045687B4 (de) * 2000-09-15 2006-07-06 MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald Expressionskassetten und Adenovirusvektoren
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
ATE466020T1 (de) 2001-11-09 2010-05-15 Univ Georgetown Neue isoform des gefässendothelzell wachstumshemmers (vegi)
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
KR100981471B1 (ko) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
EP1501855A4 (en) 2002-03-21 2006-02-22 Sagres Discovery Inc NEW COMPOSITIONS AND METHODS FOR CANCER
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP2302039A1 (en) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virus-like particles comprising HML-2 gag polypeptide
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ATE553128T1 (de) 2002-12-24 2012-04-15 Rinat Neuroscience Corp Anti-ngf-antikörper und verfahren zu ihrer verwendung
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
PL379983A1 (pl) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ATE513471T1 (de) 2003-04-21 2011-07-15 Epeius Biotechnologies Corp Verfahren und zusammensetzungen zur behandlung von erkrankungen
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
EA200601220A1 (ru) 2003-12-23 2006-12-29 Ринат Ньюросайенс Корп. Анти-trkc антитела-агонисты и способы их применения
EP1736541B1 (en) 2004-03-29 2013-01-23 Galpharma Co., Ltd. Novel modified galectin 9 protein and use thereof
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP3381930A1 (en) 2004-07-09 2018-10-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus g glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
EP2251418B1 (en) 2004-10-07 2021-03-17 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
AU2006235258A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
PL2420256T3 (pl) 2005-05-02 2016-12-30 Terapia genowa dla zaburzeń neurometabolicznych
CA2606490C (en) 2005-05-02 2018-02-06 Genzyme Corporation Gene therapy for spinal cord disorders
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
HUE036940T2 (hu) 2005-11-14 2018-08-28 Teva Pharmaceuticals Int Gmbh Kalcitonin gén-rokon peptid ellen irányuló antagonista ellenanyag
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
LT1986661T (lt) 2006-02-08 2018-12-10 Genzyme Corporation Nimano-piko a tipo ligos genų terapija
WO2007146172A2 (en) 2006-06-07 2007-12-21 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2008042420A2 (en) 2006-10-03 2008-04-10 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
AU2008250945B2 (en) 2007-05-11 2013-12-12 Alexion Pharmaceuticals, Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
CN101754682B (zh) 2007-05-16 2014-11-12 布里格姆妇女医院 突触核蛋白病的治疗
DK2158322T3 (en) 2007-06-06 2017-08-28 Genzyme Corp GENTERAPY AGAINST LYSOSOMAL STORAGE DISEASES
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102335424B (zh) * 2007-08-22 2013-12-04 中国人民解放军军事医学科学院军事兽医研究所 利用ix蛋白展示狂犬病病毒保护性抗原的犬ii型腺病毒活载体重组疫苗
WO2009042962A2 (en) 2007-09-28 2009-04-02 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
AU2008323853B8 (en) 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
AU2008337100B2 (en) 2007-12-17 2013-02-28 Pfizer Limited Treatment of interstitial cystitis
BRPI0820452A2 (pt) 2007-12-18 2015-06-16 Bioalliance Cv Anticorpos que reconhecendo um epítopo contendo um carboidrato em cd-43 e cea expressos em células cancerosas e métodos de uso dos mesmos.
CA2718975A1 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US20100180005A1 (en) * 2009-01-12 2010-07-15 Viasat, Inc. Cache cycling
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
WO2010111522A2 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
CN101560521B (zh) * 2009-06-01 2011-05-04 陕西师范大学 表达小干扰rna的va1缺失的腺病毒载体的构建方法
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
WO2011005598A1 (en) 2009-06-24 2011-01-13 University Of Southern California Compositions and methods for the rapid biosynthesis and in vivo screening of biologically relevant peptides
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
RU2443779C2 (ru) * 2009-10-09 2012-02-27 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Способ получения препарата рекомбинантного аденовируса, характеризующегося сниженным коэффициентом соотношения физических и инфекционных вирусных частиц, и генно-терапевтический лекарственный препарат, полученный таким способом
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9517250B2 (en) 2010-04-28 2016-12-13 The J. David Gladstone Institutes Methods for generating cardiomyocytes
EA024121B9 (ru) 2010-05-10 2017-01-30 Дзе Реджентс Ов Дзе Юниверсити Ов Калифорния Композиции эндорибонуклеаз и способы их использования
WO2011154553A2 (en) 2010-06-11 2011-12-15 Cellartis Ab Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
EP2698635A3 (en) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
WO2013033636A2 (en) 2011-09-01 2013-03-07 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
JP6406581B2 (ja) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー オプシンポリペプチドおよびその使用法
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CA2859472A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
PL2800811T3 (pl) 2012-05-25 2017-11-30 Emmanuelle Charpentier Sposoby i kompozycje do kierowanej RNA modyfikacji docelowego DNA i do modulacji transkrypcji kierowanej RNA
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CN104736185B (zh) 2012-08-16 2018-03-20 埃匹瑞恩股份有限公司 治疗Tau病变的方法
EP3441089B1 (en) 2012-10-17 2022-12-14 Vascular Biogenics Ltd. Treatment methods using adenovirus
CA3124553A1 (en) 2012-10-25 2014-05-01 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2014071282A1 (en) 2012-11-05 2014-05-08 Genzyme Corporation Compositions and methods for treating proteinopathies
JP2015536339A (ja) 2012-11-09 2015-12-21 ファイザー・インク 血小板由来増殖因子ｂ特異的抗体ならびにこれらの組成物および使用
US10106817B2 (en) 2013-02-14 2018-10-23 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
CA2901115A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of California Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof
US9925276B2 (en) 2013-03-14 2018-03-27 Epeius Biotechnologies Corporation Thymidine kinase gene
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
PE20151871A1 (es) 2013-05-07 2015-12-24 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
RS60883B1 (sr) 2013-06-10 2020-11-30 Ipierian Inc Metodi lečenja tauopatije
SG11201510369WA (en) 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
CN106103716A (zh) 2013-07-12 2016-11-09 乔治亚洲立大学研究基金会 Rna干扰dna聚合酶并抑制dna合成的方法及其复合物组分
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
ES2760902T3 (es) 2013-07-18 2020-05-18 Xalud Therapeutics Inc Composición para el tratamiento de la enfermedad articular inflamatoria
CN113683695A (zh) 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
EP3068801A1 (en) 2013-11-13 2016-09-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US20160298096A1 (en) 2013-11-18 2016-10-13 Crispr Therapeutics Ag Crispr-cas system materials and methods
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3080266B1 (en) 2013-12-12 2021-02-03 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EA201691787A1 (ru) 2014-03-21 2017-02-28 Тева Фармасьютикалз Интернэшнл Гмбх Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
EP3143138B1 (en) 2014-05-13 2022-03-23 BioAtla, Inc. Conditionally active biological proteins
PL3480213T3 (pl) 2014-06-18 2020-05-18 Albert Einstein College Of Medicine Polipeptydy syntac i ich zastosowania
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016022994A2 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University High affinity pd-1 agents and methods of use
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
JP2017532019A (ja) 2014-09-03 2017-11-02 バイオアトラ、エルエルシー 同じ真核細胞産生宿主における条件的活性型生物学的タンパク質の発見及び作製
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
MA40595A (fr) 2014-09-09 2021-05-26 Unum Therapeutics Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3268472B1 (en) 2015-03-13 2021-05-05 The Jackson Laboratory A three-component crispr/cas complex system and uses thereof
US20180071340A1 (en) 2015-03-30 2018-03-15 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating multiple myeloma
US11026921B2 (en) 2015-03-30 2021-06-08 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US20180078626A1 (en) 2015-03-30 2018-03-22 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating renal cell cancer
US20180085398A1 (en) 2015-03-30 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
CA2977753A1 (en) 2015-03-30 2016-10-06 Beth Israel Deaconess Medical Center Compositions and methods of treating acute myeloid leukemia
LT3280440T (lt) 2015-04-06 2023-02-27 Bioverativ Usa Inc. Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
AU2016246655B2 (en) 2015-04-07 2021-07-22 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods for inducing cell division of postmitotic cells
CA2925329C (en) 2015-04-13 2024-01-02 Pfizer Inc. Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3
AU2016256895B2 (en) 2015-05-07 2022-05-26 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US11040094B2 (en) 2015-07-01 2021-06-22 Colleen M. O'Connor Compositions and methods for treating immunological dysfunction
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3331536A4 (en) 2015-08-03 2019-03-27 The Regents of The University of California COMPOSITIONS AND METHODS FOR MODULATING ABHD2 ACTIVITY
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
AU2016316730B2 (en) 2015-09-02 2023-05-25 Immutep S.A.S. Anti-LAG-3 Antibodies
CA3036652A1 (en) 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AU2016339053A1 (en) 2015-09-24 2018-04-12 Crispr Therapeutics Ag Novel family of RNA-programmable endonucleases and their uses in genome editing and other applications
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3362472B1 (en) 2015-10-16 2023-08-30 The Trustees of Columbia University in the City of New York Compositions and methods for inhibition of lineage specific antigens
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
US20200323952A1 (en) 2015-11-20 2020-10-15 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
SG11201804038VA (en) 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
WO2017151940A2 (en) 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018009923A1 (en) 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2017165245A2 (en) 2016-03-19 2017-09-28 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulated expansion thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US20190125848A1 (en) 2016-03-30 2019-05-02 Dana-Farber Cancer Institute, Inc. Dendritic cell-extracellular vesicle fusions and methods of using same
AU2017246794A1 (en) 2016-04-04 2018-10-25 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
EP4122958A1 (en) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CA3036695A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted enhanced dna demethylation
US10578610B2 (en) 2016-09-20 2020-03-03 Washington University Peptide regulators of mitochondrial fusion and methods of use
IL265957B2 (en) 2016-10-12 2024-04-01 Bioverativ Usa Inc Anti-C1S antibodies and methods of using them
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US20200000896A1 (en) 2016-11-14 2020-01-02 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US20190269775A1 (en) 2016-11-14 2019-09-05 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US11261428B2 (en) 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
IL266696B2 (en) 2016-12-22 2023-04-01 Cue Biopharma Inc Multimeric polypeptides modulate t cells and methods for their use
EP3565834A1 (en) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
BR112019013862A2 (pt) 2017-01-07 2020-04-14 Selecta Biosciences Inc dosagem padrão de imunossupressores acoplados a nanocarreadores sintéticos
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018136566A1 (en) 2017-01-18 2018-07-26 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
US20190367621A1 (en) 2017-01-18 2019-12-05 F1 Oncology, Inc. Chimeric antigen receptors against axl or ror2 and methods of use thereof
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
KR20200003370A (ko) 2017-03-03 2020-01-09 에프1 온콜로지, 인코포레이티드 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
JP2020510435A (ja) 2017-03-03 2020-04-09 ライナット ニューロサイエンス コーポレイション 抗ｇｉｔｒ抗体およびその使用方法
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
PE20191846A1 (es) 2017-06-02 2019-12-31 Pfizer Anticuerpos especificos para flt3 y sus usos
DE112018002990T5 (de) 2017-06-13 2020-04-02 Bostongene Corporation Systeme und verfahren zum erzeugen, visualisieren und klassifizieren von molekularen funktionellen profilen
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
BR112019027765A2 (pt) * 2017-07-25 2020-07-14 Oxford Genetics Limited vetores adenovirais
KR20200064085A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
IL302614A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2019051122A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
JP2020536115A (ja) 2017-10-04 2020-12-10 オプコ ファーマシューティカルズ、エルエルシー 癌の個別化療法に関する物品および方法
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2019118935A1 (en) 2017-12-14 2019-06-20 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and their use in genome editing and other applications
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
US11396551B2 (en) 2018-02-01 2022-07-26 Pfizer Inc. Chimeric antigen receptors targeting CD70
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
US11667949B2 (en) 2018-02-15 2023-06-06 The Trustees Of Princeton University Reporter construct and biosensor for interferon second messenger 2-5A
CN112384204B (zh) 2018-02-26 2023-03-14 安托瑞斯公司 致耐受性脂质体及其使用方法
RU2020128440A (ru) 2018-02-28 2022-03-28 Пфайзер Инк. Варианты il-15 и их применения
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
EP3768834A1 (en) 2018-03-19 2021-01-27 CRISPR Therapeutics AG Novel rna-programmable endonuclease systems and uses thereof
TWI816396B (zh) 2018-05-23 2023-09-21 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
JP7384835B2 (ja) 2018-05-23 2023-11-21 ファイザー・インク Ｃｄ３に特異的な抗体及びその使用
CN112672790A (zh) 2018-08-09 2021-04-16 马弗里克治疗公司 条件性活化的结合蛋白的共表达和纯化方法
SG11202101421RA (en) * 2018-08-16 2021-03-30 Spacecraft Seven Llc Production methods for viral vectors
EP3844187A1 (en) 2018-08-28 2021-07-07 Vor Biopharma, Inc. Genetically engineered hematopoietic stem cells and uses thereof
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
WO2020073004A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
TW202039542A (zh) 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
JP2022524337A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質
EP3934762A1 (en) 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
WO2020181062A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN113811607A (zh) 2019-03-07 2021-12-17 加利福尼亚大学董事会 CRISPR-Cas效应子多肽和其使用方法
CA3132630A1 (en) 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
US20220204627A1 (en) 2019-04-02 2022-06-30 Kenjockety Biotechnology, Inc. Efflux Pump-Cancer Antigen Multi-Specific Antibodies and Compositions, Reagents, Kits and Methods Related Thereto
MX2021013163A (es) 2019-04-28 2022-02-21 Selecta Biosciences Inc Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
WO2021007260A2 (en) 2019-07-08 2021-01-14 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
WO2021113736A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Single-domain antibody to chloramphenicol
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
IL295989A (en) 2020-03-02 2022-10-01 Tenaya Therapeutics Inc Gene vector control using cardiomyocyte expression microRNA
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
EP4146688A1 (en) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Mask peptides and masked anti-ptk7 antibodies comprising such
CA3182969A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
PE20231565A1 (es) 2020-07-17 2023-10-04 Pfizer Anticuerpos terapeuticos y sus usos
WO2022023972A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
EP4176058A1 (en) 2020-08-07 2023-05-10 The Jackson Laboratory Targeted sequence insertion compositions and methods
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2022120256A2 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
WO2022232615A1 (en) 2021-04-29 2022-11-03 Bostongene Corporation Machine learning techniques for estimating tumor cell expression complex tumor tissue
CA3222756A1 (en) 2021-06-10 2022-12-15 Janssen Biotech, Inc. Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
EP4352214A1 (en) 2021-06-11 2024-04-17 Bayer AG Type v rna programmable endonuclease systems
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
AU2022349103A1 (en) 2021-09-27 2024-03-28 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023102388A1 (en) 2021-11-30 2023-06-08 Sanofi Pasteur Inc. Human metapneumovirus viral vector-based vaccines
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024005863A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
WO2024005864A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4299733A1 (en) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4299739A1 (en) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024044659A1 (en) 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567253A (en) * 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0746625B1 (en) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targetable vector particles
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
AU7019494A (en) * 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
RU2162342C2 (ru) * 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
US20050031590A9 (en) * 1993-10-25 2005-02-10 Richard Gregory Adenoviral vectors having a protein IX deletion
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US6333030B1 (en) * 1996-11-19 2001-12-25 Uab Research Foundation Chimeric retrovirus/adenovirus system
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
CA2283461A1 (en) * 1997-03-14 1998-09-17 Uab Research Foundation Adenoviral vectors with modified tropism

Also Published As

Publication number Publication date
ES2256842T3 (es) 2006-07-16
HUT77575A (hu) 1998-06-29
SK51096A3 (en) 1996-10-02
CA2173975C (en) 2007-06-12
CA2173975A1 (en) 1995-05-04
EP0797676B9 (en) 2006-06-28
EP1637608A2 (en) 2006-03-22
ATE314482T1 (de) 2006-01-15
AU687117B2 (en) 1998-02-19
HU223733B1 (hu) 2004-12-28
CN1147837A (zh) 1997-04-16
ES2328585T3 (es) 2009-11-16
NZ275956A (en) 1997-09-22
CN1263864C (zh) 2006-07-12
EP2113569A1 (en) 2009-11-04
PL314239A1 (en) 1996-09-02
CZ114396A3 (en) 1996-11-13
EP1637608B1 (en) 2009-07-22
WO1995011984A2 (en) 1995-05-04
US20080182807A1 (en) 2008-07-31
DE69435223D1 (de) 2009-09-03
US20090082289A1 (en) 2009-03-26
CZ291372B6 (cs) 2003-02-12
RU2162342C2 (ru) 2001-01-27
US20080299083A1 (en) 2008-12-04
JP3875990B2 (ja) 2007-01-31
EP0797676A2 (en) 1997-10-01
WO1995011984A3 (en) 1995-07-06
EP1637608A3 (en) 2006-04-05
PL186073B1 (pl) 2003-10-31
NO961639L (no) 1996-06-24
ES2256842T4 (es) 2007-02-01
DE69434594T2 (de) 2006-09-21
JPH09507051A (ja) 1997-07-15
FI961755A (fi) 1996-06-04
US20090088398A1 (en) 2009-04-02
ATE437232T1 (de) 2009-08-15
HU9601073D0 (en) 1996-06-28
AU8125094A (en) 1995-05-22
DK0797676T3 (da) 2006-04-18
FI961755A0 (fi) 1996-04-24
EP0797676B1 (en) 2005-12-28
DE69434594D1 (de) 2006-02-02
BR9407956A (pt) 1996-11-26
PT797676E (pt) 2006-05-31
SK283703B6 (sk) 2003-12-02
US20080175818A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
NO961639L (no) Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
DK1489097T3 (da) Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
ATE394484T1 (de) Smad 6 und dessen anwendungen
GR852940B (no)
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
FI962114A (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
DE69738803D1 (de) Apoptosis induzierendes protein und dieses kodierendes gen
WO2004035799A3 (de) Virale vektoren und deren verwendung für die gentherapie
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
ES2170082T3 (es) Transactivador de mhc clase ii (ciita) y sus usos.
ATE402259T1 (de) Lage-1 tumor-assozierte nukleinsäuren
IL108584A0 (en) Cloning of interferon - alpha beta binding protein
DK0386733T3 (da) cDNA, som koder for placentaprotein 9 (PP9), dets isolering og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application